Halozyme adds Dannielle Appelhans to board of directors
Halozyme Therapeutics disclosed the August 14, 2026 board appointment in an 8-K filed with the SEC.
Halozyme Therapeutics, Inc. said in an SEC filing that Dannielle Appelhans joined the company's Board of Directors on August 14, 2026.1
Her board term places her in the class of directors whose terms run until the company's 2028 annual meeting of stockholders, and she has not yet been assigned to a board committee.1
On compensation, the filing states that Appelhans will be paid under Halozyme's standard non-employee director program, which currently includes cash retainers for board and committee service along with restricted stock and stock option grants, subject to any future revisions.1 The filing notes that the details of that compensation program were laid out in the company's proxy statement for its 2026 Annual Meeting of Stockholders, held on May 5, 2026.1
Halozyme also stated that no arrangements or understandings led to her election, and that no related person transactions exist between the company and Appelhans.1
The 8-K was signed by Mark Snyder, Halozyme's Executive Vice President, General Counsel and Corporate Secretary, and dated August 18, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.